{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:16:10Z","timestamp":1778220970716,"version":"3.51.4"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This systematic review and network meta-analysis synthesizes evidence from randomized controlled trials (RCTs) investigating three novel glucose-lowering therapies in patients with coexisting heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus(T2DM). We evaluated composite cardiovascular outcomes in this high-risk cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search without language restrictions was performed across PubMed, EMBASE, and the Cochrane Library from inception to September 1, 2025. The network meta-analysis assessed the following endpoints: Composite of cardiovascular death and heart failure hospitalization; Hospitalization for heart failure; Left ventricular ejection fraction (LVEF); N-terminal pro-B-type natriuretic peptide (NT-proBNP); Estimated glomerular filtration rate (eGFR); Glycated hemoglobin (HbA1c). Quality appraisal of included RCTs using the Cochrane Risk of Bias Tool 2.0 (ROB2) and Confidence in Network Meta-Analysis (CINeMA) for grading evidence certainty. The study protocol was prospectively registered with PROSPERO (CRD420251269519).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final analysis pooled data from 16 randomized trials encompassing 14,710 patients. For the composite of cardiovascular death or hospitalization for heart failure, Sotagliflozin demonstrated the most substantial risk reduction (OR\u2009=\u20090.49; 95% CI 0.39, 0.62). This agent also showed significant efficacy against heart failure readmission (OR\u2009=\u20090.53; 95% CI 0.45, 0.63). Notably, Dapagliflozin improved LVEF more effectively than controls (MD \u22122.94%; 95% CI \u22123.89, \u22121.99). Among patients with HFrEF and T2DM, Empagliflozin significantly reduced NT-proBNP plasma levels vs. placebo (SMD \u22120.61; 95% CI \u22120.91, \u22120.31). Empagliflozin additionally exhibited superior preservation of eGFR (MD \u22122.08; 95% CI \u22123.38, \u22120.78), whereas Vildagliptin achieved the greatest reduction in HbA1c (MD \u22120.62%; 95% CI \u22121.12, \u22120.12).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis provides evidence that Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) may be associated with a reduction in major adverse cardiovascular events (MACE) and exert superior renoprotective effects in patients with HFrEF and comorbid T2DM. Notably, Sotagliflozin demonstrates potentially favorable effects for primary cardiovascular endpoints, whereas Vildagliptin appears to be more effective for HbA1c reduction in this analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD420251269519.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1799254","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:12Z","timestamp":1778219772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the therapeutic effect of new hypoglycemic drugs on patients with heart failure with reduced ejection fraction and type 2 diabetes: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xin-Rao","family":"Chen","sequence":"first","affiliation":[{"name":"West China Hospital Sichuan University, Meishan Hospital","place":["Meishan, China"]},{"name":"Department of General Practice, Meishan People\u2019s Hospital","place":["Meishan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-ping","family":"Mao","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University, Meishan Hospital","place":["Meishan, China"]},{"name":"Department of General Practice, Meishan People\u2019s Hospital","place":["Meishan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University, Meishan Hospital","place":["Meishan, China"]},{"name":"Department of General Practice, Meishan People\u2019s Hospital","place":["Meishan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-qing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicin, Bishan Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-ning","family":"Bai","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University, Meishan Hospital","place":["Meishan, China"]},{"name":"Department of General Practice, Meishan People\u2019s Hospital","place":["Meishan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Borja","year":"2017","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5603\/KP.2019.0018","article-title":"[2018 ESC\/ESH guidelines for the management of arterial hypertension]","volume":"77","author":"Williams","year":"2019","journal-title":"Kardiol Pol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6976153","DOI":"10.1155\/2020\/6976153","article-title":"Type 2 diabetes Mellitus and chronic heart failure with midrange and preserved ejection fraction: a focus on Serum biomarkers of fibrosis","volume":"2020","author":"Lebedev","year":"2020","journal-title":"J Diabetes Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10741-012-9313-3","article-title":"Diabetic cardiomyopathy: pathophysiology and clinical features","volume":"18","author":"Miki","year":"2012","journal-title":"Heart Fail Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes Mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","article-title":"Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study","volume":"116","author":"McGavock","year":"2007","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","article-title":"Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry","volume":"23","author":"Zhang","year":"2017","journal-title":"J Card Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/01.RES.0000207406.94146.c2","article-title":"Diabetic cardiomyopathy: the search for a unifying hypothesis","volume":"98","author":"Poornima","year":"2006","journal-title":"Circ Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/eurheartj\/ehn156","article-title":"Diabetes, left ventricular systolic dysfunction, and chronic heart failure","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes Mellitus and heart failure: a scientific statement from the American Heart Association and the heart failure society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2020","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular biology of the incretin system","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cardfail.2014.10.012","article-title":"Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes","volume":"21","author":"Velez","year":"2014","journal-title":"J Card Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27235","DOI":"10.1074\/jbc.M114.557835","article-title":"Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism","volume":"289","author":"Ishii","year":"2014","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1475-2840-13-43","article-title":"Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats","volume":"13","author":"Miyoshi","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","year":"2022","journal-title":"J Card Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00059-021-05084-5","article-title":"[Guidelines of the ESC 2021 on heart failure]","volume":"47","author":"Bauersachs","year":"2021","journal-title":"Herz"},{"key":"B33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12933-025-03072-1","article-title":"Age-specific associations between blood pressure and cardiovascular disease, kidney disease, and death among individuals with type 2 diabetes: a population-based cohort study","volume":"25","author":"Chow","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3760\/cma.j.issn.0254-6450.2018.02.020","article-title":"[Risk related to bias assessment: (4) revised cochrane risk of bias tool for cluster-randomized control trials (RoB2.0)]","volume":"39","author":"Lyu","year":"2018","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12872-023-03591-3","article-title":"Effect of SGLT-2 inhibitor, dapagli0ozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"B37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/00015385.2023.2240130","article-title":"Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction","volume":"79","author":"Afshani","year":"2024","journal-title":"Acta Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes Mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/00015385.2023.2243130","article-title":"DAPA-HF applicability: the point of view of a cardiology setting","volume":"78","author":"Iacoviello","year":"2023","journal-title":"Acta Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2016.01.008","article-title":"Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction","volume":"4","author":"Lepore","year":"2016","journal-title":"JACC Heart Fail"},{"key":"B41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of vildagliptin on ventricular function in patients with type 2 diabetes Mellitus and heart failure: a randomized placebo-controlled trial","volume":"6","author":"McMurray","year":"2017","journal-title":"JACC Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/dom.14135","article-title":"The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes","volume":"22","author":"Nielsen","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes Status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2020","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin versus placebo on symptoms and 6-Minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2023","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1002\/ehf2.13553","article-title":"Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial","volume":"8","author":"Ilyas","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/ejhf.3269","article-title":"Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: a pre-specified analysis of the DELIVER trial","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/0115748871323540241212060946","article-title":"Empagliflozin ameliorates the oxidative stress profile in type 2 diabetic patients with heart failure and reduced ejection fraction: results of a randomized, double-blind, placebo-controlled study","volume":"20","author":"Eshraghi","year":"2025","journal-title":"Rev Recent Clin Trials"},{"key":"B49","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.ihj.2023.11.109","article-title":"Open-label, randomized, multi-centre study to evaluate safety and efficacy of remogliflozin in patients with type 2 diabetes mellitus with acute decompensated heart failure (HF with reduced ejection fraction, HFrEF). (remo safe-AHF study)[J]","volume":"75","author":"Bhushan","year":"2023","journal-title":"Indian Heart J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1002\/ehf2.13148","article-title":"Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: sOLOIST-WHF in perspective","volume":"7","author":"Verma","year":"2020","journal-title":"ESC Heart Failure"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1517\/13543784.2015.1100361","article-title":"Sotagliflozin as a potential treatment for type 2 diabetes mellitus","volume":"24","author":"Cariou","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"B54","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/postmj\/qgae148","article-title":"Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis","volume":"101","author":"Song","year":"2024","journal-title":"Postgrad Med J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cjca.2019.11.036","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O'Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"B57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/s0735-1097(99)00630-0","article-title":"Cardiac remodeling\u2013concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/bjp.2008.189","article-title":"Chronic inhibition of the na+\/H+\u2014exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling","volume":"154","author":"Baartscheer","year":"","journal-title":"Br J Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2016","journal-title":"Diabetologia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yjmcc.2013.02.006","article-title":"NHE-1: still a viable therapeutic target","volume":"61","author":"Karmazyn","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B65","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0\u2005mg vs once-daily liraglutide 1.2\u2005mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (sustain 10)","volume":"46","author":"Capehorn","year":"","journal-title":"Diabetes Metab"},{"key":"B68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.diabres.2017.09.006","article-title":"Liraglutide ameliorates early renal injury by the activation of renal Foxo1 in a type 2 diabetic kidney disease rat model","volume":"137","author":"Pin","year":"","journal-title":"Diabetes Res Clin Pract"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2337\/db11-1824","article-title":"Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC\u03b2 activation in diabetes","volume":"61","author":"Mima","year":"2012","journal-title":"Diabetes"},{"key":"B70","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1159\/000509418","article-title":"Liraglutide improves the kidney function in a murine model of chronic kidney disease","volume":"144","author":"Maria","year":"","journal-title":"Nephron"},{"key":"B71","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0168396","DOI":"10.1371\/journal.pone.0168396","article-title":"Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-\/- mice","volume":"11","author":"Bisgaard","year":"2016","journal-title":"PLoS One"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00592-023-02124-w","article-title":"Glp-1ras and cardiovascular disease: is the endothelium a relevant platform?","volume":"60","author":"Rossella","year":"","journal-title":"Acta Diabetol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes in0ammatory pathways","volume":"3","author":"Rakipovski","year":"","journal-title":"JACC Basic Transl Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"B78","first-page":"1003","article-title":"SAVOR-TIMI 53 - vysledky saxagliptinu a kardiovaskularni vysledky u pacientu s diabetes mellitus 2. Typu [SAVORTIMI 53 - saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus]","volume":"59","author":"Spinar","year":"2013","journal-title":"Vnitr Lek"},{"key":"B79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1475-2840-13-3","article-title":"Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials","volume":"13","author":"Iqbal","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/medicina59101760","article-title":"Associations between oral glucose-lowering agents and increased risk for lifethreateningarrhythmias in patients with type 2 diabetes Mellitus-a literaturereview","volume":"59","author":"Cristina","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/jpm12020271","article-title":"Clinical observation of Sglt2 inhibitor therapy for cardiac arrhythmia andrelated cardiovascular disease in diabetic patients with controlled hypertension","volume":"12","author":"Shih-Jie","year":"2022","journal-title":"J Pers Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1799254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:14Z","timestamp":1778219774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1799254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":81,"alternative-id":["10.3389\/fcvm.2026.1799254"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1799254","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1799254"}}